The estimated Net Worth of William Wei Zuo is at least $1.93 millió dollars as of 4 March 2021. William Zuo owns over 419,931 units of Athenex Inc stock worth over $28,577 and over the last 7 years he sold ATNX stock worth over $1,898,088. In addition, he makes $0 as President és China Division at Athenex Inc.
Sign up
William Zuo ATNX stock SEC Form 4 insiders trading
William has made over 2 trades of the Athenex Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 419,931 units of ATNX stock worth $1,898,088 on 4 March 2021.
The largest trade he's ever made was selling 419,931 units of Athenex Inc stock on 4 March 2021 worth over $1,898,088. On average, William trades about 46,770 units every 79 days since 2017. As of 4 March 2021 he still owns at least 142,883 units of Athenex Inc stock.
You can see the complete history of William Zuo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Zuo biography
Dr. William W. Zuo Ph.D. serves as President, China Division of the Company. Dr. Zuo joined our company in 2015 as President of our China operations in conjunction with our acquisition of Polymed Therapeutics. Dr. Zuo had served as President of Polymed Therapeutics since 1995 and Chairman of Chongqing Taihao Pharmaceutical since 2012. Dr. Zuo’s career has focused on the development, manufacture, and sale and marketing of various complex API on a global basis, especially injectable oncology active pharmaceutical ingredients. Dr. Zuo was the chief executive officer of the Fibrocell Science Group Companies in Asia from 2010 to 2013. Dr. Zuo oversaw the introduction of the U.S. FDA approved cell therapeutics product, LaViv, to the Asia market. He has overseen the construction of multiple current Good Manufacturing Practices (“cGMP”) facilities in China and has extensive experience with the Food and Drug Administrations in both China and the United States. Dr. Zuo received his Ph.D in Nanotechnology from Rice University where he worked extensively with Dr. Richard Smalley, the late Nobel Prize Scholar in Chemistry. Dr. Zuo also has Master degrees in Chemical Engineering and Applied Mathematics from Rice University.
How old is William Zuo?
William Zuo is 58, he's been the President és China Division of Athenex Inc since 2015. There are 12 older and 5 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
What's William Zuo's mailing address?
William's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Insiders trading at Athenex Inc
Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang és Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.
What does Athenex Inc do?
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
What does Athenex Inc's logo look like?
Complete history of William Zuo stock trades at Athenex Inc
Athenex Inc executives and stock owners
Athenex Inc executives and other stock owners filed with the SEC include:
-
Johnson Lau,
Chief Executive Officer and Chairman of the Board -
Rudolf Kwan,
Chief Medical Officer -
Jeffrey Yordon,
Chief Operating Officer and President, Athenex Pharmaceutical Division -
Randoll Sze,
Chief Financial Officer -
Simon Pedder,
Chief Business and Strategy Officer - Proprietary Products -
Jeffrey M. Yordon,
COO & Pres of Athenex Pharmaceutical Division -
Dr. Rudolf Kwan M.D., M.B., B.S.,
Chief Medical Officer -
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
Chairman & CEO -
Benson Tsang,
Independent Director -
Stephanie Davis,
Independent Director -
Kim Campbell,
Lead Independent Director -
Jinn Wu,
Independent Director -
Jordan Kanfer,
Independent Director -
John Vierling,
Independent Director -
Manson Fok,
Director -
Robert Spiegel,
Director -
Daniel Lang,
Senior Director - Corporate Development, President - Axis Therapeutics Limited -
Tim McCarthy,
IR Contact Officer -
William Zuo,
President, China Division -
Dr. Wing-Kai Chan,
Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms -
John W. Matthei,
VP of HR -
Caileigh Dougherty,
Director of Investor Relations -
Michael Smolinski Ph.D.,
Chief Scientific Officer -
Steven J. Adams,
Interim Chief Accounting Officer -
Daniel Lang M.D.,
Sr. Director of Corp. Devel. -
Jacqueline Li,
Director of Corp. Devel. & Investor Relations -
Steven Rubis,
Sr. Director of Investor Relations -
Teresa Brophy Bair,
Gen. Counsel, Sr. VP of Admin. & Corp. Sec. -
Dr. Allen Barnett,
Co-Founder & Pres Emeritus -
James Zukin,
-
Michael D Cannon,
-
J Nick Riehle,
Chief Financial Officer -
Antony Leung,
-
Song Yi Zhang,
Director -
John Koh,
Director -
Advisors Llcperceptive Life...,
-
Sheldon Trainor Degirolamo,
Director -
Timothy De Vere Cook,
See Remarks -
Teresa Brophy Bair,
General Counsel, SVP Admin. -
Joe Annoni,
Chief Financial Officer -
Steven J. Adams,
Interim Chief Acct Officer -
Michael Smolinski,
Chief Scientific Officer